An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602
This is a phase 3 multicentre, randomized, open label study designed to evaluate the
clinical benefit and safety of the combination therapy of Nivolumab, pomalidomide, and
dexamethasone (N-Pd the investigational arms, when compared to pomalidomide and
dexamethasone (Pd; the control arm) in subjects with relapsed and refractory multiple
myeloma (rrMM). The study includes a third arm evaluating the clinical benefit and the
safety of the combination therapy of elotuzumab, nivolumab, pomalidomide and dexamethasone
(NE-Pd, the exploratory arm) in the same patient population. Subjects in the control arm
(Pd) are allowed to cross-over to the exploratory arm (EN-Pd) at the time of progression.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society